a study to evaluate the safety, tolerability, pharmacokinetics (pk), pharmacodynamics (pd), and preliminary activity of tiragolumab in participants with relapsed or refractory multiple myeloma or with relapsed or refractory b-cell non-hodgkin lymphoma

Conditions: Multiple Myeloma; Non-Hodgkin Lymphoma; B-Cell Lymphoma

Summary: this is a phase i open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary activity of tiragolumab administered as a single agent or in combination with atezolizumab and/or daratumumab or rituximab in participants with relapsed or refractory (r/r) multiple myeloma (mm) or r/r non-hodgkin lymphoma (nhl).

in the phase ia part of the study, tiragolumab is administered as a single agent in participants with r/r mm or r/r nhl. in the phase ib part of the study, tiragolumab is administered in combination with atezolizumab and/or daratumumab in participants with r/r mm or with rituximab in participants with r/r nhl.

Eligibility criteria:
inclusion criteria: general inclusion criteria (all participants): * eastern cooperative oncology group (ecog) performance status of 0 or 1 * life expectancy of \>/= 12 weeks inclusion criteria specific to arms a, c and e (r/r mm): * arm a only: must have r/r mm for which no established therapy for mm is appropriate and available or be intolerant to those established therapies * arms c and e only: participants with r/r mm who have received at least 3 prior lines of therapy. * measurable disease defined by laboratory test results. inclusion criteria specific to arms b and d (r/r nhl): * participants with histologically confirmed b-cell nhl who have relapsed or failed to respond to at least two prior systemic treatment regimens and for which no suitable therapy of curative intent or higher priority exists. * must have at least one bi-dimensionally measurable lesion. exclusion criteria: general exclusion criteria (all participants): * any anti-cancer therapy, whether investigational or approved, including chemotherapy, monoclonal antibody, radioimmunoconjugate, antibody-drug conjugate, hormonal therapy, and/or radiotherapy, within 4 weeks or 5 half-lives of the drug, whichever is shorter, prior to initiation of study treatment * prior treatment with any anti-tigit agent * prior treatment with chimeric antigen receptor-t (car-t) therapy within 12 weeks before first study drug administration * autologous stem-cell transplantation (asct) within 100 days prior to first study drug administration * active or history of autoimmune disease or immune deficiency * known active bacterial, viral (including sars-cov-2), fungal, mycobacterial, parasitic, or other infection at study enrollment, or any major episode of infection within 4 weeks prior to first study drug administration exclusion criteria specific to arms a, c and e (r/r mm): * primary or secondary plasma cell leukemia * current or history of cns involvement by mm exclusion criteria specific to arms b and d (r/r nhl): * uncontrolled hypercalcemia or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy or denosumab * current or history of cns lymphoma * current eligibility for asct other protocol defined inclusion/exclusion criteria could apply